Bioqube Ventures, an emerging life sciences investment firm, is pleased to announce the appointment of Tom Heyman as Executive Partner, joining the firm’s leadership team.
Tom Heyman is a seasoned pharma executive with more than 40 years of experience in general management, business development, and equity investments. He spent his entire career at Johnson & Johnson and its affiliates in both the United States and Belgium.
He joined Bioqube in 2020 as an Operating Partner following his departure from Johnson & Johnson. During his tenure there, he served on the Group Operating Committee and the Pharmaceutical Group’s Executive Committee and was President of Johnson & Johnson Innovation – JJDC, the company’s venture capital arm. Prior to that, he held senior roles including Global Head of Business Development for Johnson & Johnson’s Pharmaceutical Group and Managing Director of Janssen Pharmaceutica in Belgium. He began his career in Janssen Belgium’s legal department and relocated to the United States in 1990 as Vice President of Licensing at Ortho Pharmaceutical, another Johnson & Johnson affiliate.
The appointment of Tom comes at a pivotal moment for Bioqube. The company is entering a new growth phase in which it is expanding its international activities and strengthening its presence in the United States, in parallel with the launch of its next fund. This milestone accelerates the company’s global reach and reinforces its mission to connect European innovation with U.S. capital and expertise.
“As we enter the next chapter of Bioqube’s growth, our focus on executing our investment strategy remains unwavering,” said Nico Vandervelpen, Co-Founder and Managing Partner at Bioqube Ventures. “Tom’s transatlantic expertise and network, combined with the growth of our broader team, will accelerate our international ambitions and help our portfolio companies grow and thrive.”
“Strategic build-out of our team is core to our success. Tom’s transition to our leadership team represents an important step in Bioqube’s international expansion, bolstering our reach and influence in both Europe and the U.S.,” said Debora Dumont, Co-Founder and Managing Partner at Bioqube Ventures. “Beyond his strategic acumen, Tom embodies the values we stand for and serves as a mentor whose guidance will help our younger team members evolve into the leaders of tomorrow.”
“I am honored to join Bioqube’s leadership team at such an exciting stage in the firm’s journey,” said Tom Heyman. “Together, we are committed to advancing groundbreaking therapeutics and building companies that create meaningful impact for patients. I look forward to contributing my experience to accelerate both new and existing opportunities across the portfolio.”
Tom holds a Master of Law degree from the University of Leuven and pursued postgraduate studies in business management at the University of Antwerp and at the Université des Hautes Études Internationales in Geneva. He currently serves on the Board of Directors of Imec, Akero Therapeutics (NASDAQ: AKRO), Exelixis (NASDAQ: EXEL), and Legend Biotech (NASDAQ: LEG), and represents Bioqube on the boards of several portfolio companies.